Lexicon Pharmaceuticals (LXRX)

• Market cap: $407M
• 1 day: -2.61%
• 5 days: 4.67%
• 1 month: -9.68%
• 3 months: 67.16%
• 6 months: 191.44%
• Year to date: 44.13%
• 1 year: -31.29%
• 5 years: -29.56%
• 10 years: -92.01%
• Sector: Healthcare
• Industry: Biotechnology

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Employees: 103

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

455% more call options, than puts

Call options by funds: $805K | Put options by funds: $145K

98% more capital invested

Capital invested by funds: $122M [Q1] → $243M (+$121M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

2.95% less ownership

Funds ownership: 73.53% [Q1] → 70.58% (-2.95%) [Q2]

3% less funds holding

Funds holding: 126 [Q1] → 122 (-4) [Q2]

11% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 36

13% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 32

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.9
• Avg. target: $2.95
• High target: $4

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis	$4	Buy Reiterated	2 Sep 2025
Citigroup Yigal Nochomovitz	$1.9	Buy Maintained	7 Aug 2025